(2R)-2-甲基-4,4,4-三氟丁醇 | 136655-98-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (2R)-2-甲基-4,4,4-三氟丁醇
• 英文名称: (2R)-4,4,4-trifluoro-2-methylbutan-1-ol
• 英文别名: (R)-2-methyl-4,4,4-trifluorobutan-1-ol；1-Butanol, 4,4,4-trifluoro-2-methyl-, (2R)-
• CAS: 136655-98-6
• 化学式: C₅H₉F₃O
• 分子量: 142.121
• InChiKey: SSXCXTKPQAFQAP-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R)-2-甲基-4,4,4-三氟丁醇 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 碘苯二乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以90%的产率得到(2R)-4,4,4-trifluoro-2-methylbutanal
  参考文献：
  名称：

  Practical asymmetric synthesis of a novel γ-secretase inhibitor

  摘要：

  An efficient route to gamma-secretase inhibitor hydroxyl thiophene sulfonamide 1 is described. The approach contains nine steps with an overall yield of 8%. The synthesis highlights a diastereoselective methylation using Evans' oxazolidinone method and a chiral Strecker reaction via Davis' sulfonimine protocol. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.04.072
• 作为产物：
  描述：

  (4R,5S)-3-((2R)-2-methyl-1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以57%的产率得到(2R)-2-甲基-4,4,4-三氟丁醇
  参考文献：
  名称：

  Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-Indolecarboxamides: Identification of 4-[[5-[((2R)-2-Methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a Potent, Orally Active Antagonist of Leukotrienes D4 and E4

  摘要：

  The continued exploration of a series of 3-(arylmethyl)-1H-indole-5-carboxamides by the introduction of fluorinated amide substituents has resulted in the discovery of 4-[[5-[((2R)-2-methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide (38p, ZENECA ZD 3523),which has been chosen for clinical evaluation. This compound exhibited a K-i of 0.42 nM for displacement of [H-3]LTD(4) on guinea pig lung membranes, a pK(B) Of 10.13 +/- 0.14 versus LTE(4) on guinea pig trachea, and an oral ED(50) Of 1.14 mu mol/kg opposite LTD(4)-induced bronchoconstriction in guinea pigs. The R enantiomer was found to be modestly more potent than the S enantiomer 38o. Modification of the amide substituent to afford achiral compounds was unsuccessful in achieving comparable levels of activity. Profiling of 38p opposite a variety of functional assays has demonstrated the selectivity of this compound as a leukotriene receptor antagonist. The enantioselective synthesis of 38p, which employed a diastereoselective alkylation of (4R,5S)-3-(1-oxo-4,4,4-trifluorobutyl)-4-methyl-5-phenyl-2-oxazolidinone (27) as the key step to establish the chirality of the amide substituent, provided an efficient route for generating 38p in >99% enantiomeric purity.

  DOI：

  10.1021/jm00035a008

文献信息

• Carbamoyl derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US05286740A1

  公开（公告）日：1994-02-15

  The present invention concerns novel carbamoyl derivatives of formula I, set out herein, which antagonize the pharmacological actions of one or more of the arachidonic acid metabolites known as leukotrienes, making them useful whenever such antagonism is desired, such as in the treatment of those diseases in which leukotrienes are implicated, for example, in the treatment of allergic or inflammatory diseases, or of endotoxic or traumatic shock conditions. The invention also provides pharmaceutical compositions containing the novel derivatives for use in such treatments, methods for their use and processes and intermediates for the manufacture of the novel derivatives.

  本发明涉及一种新的氨基甲酰衍生物，其化学式为I，该衍生物在此处列出，能拮抗被称为白三烯的花生四烯酸代谢产物的药理作用，使其在需要拮抗这种作用的情况下非常有用，例如在白三烯参与的疾病治疗中，例如在过敏性或炎症性疾病的治疗中，或在内毒素性或创伤性休克症状的治疗中。该发明还提供了含有这些新衍生物的药物组合物，用于进行这种治疗的方法，以及用于制造这些新衍生物的方法和中间体。
• Chemical process for the preparation of 3-alkylated indole
  申请人：Imperial Chemical Industries PLC

  公开号：US05280125A1

  公开（公告）日：1994-01-18

  A process for the preparation of a 3-alkylated indole, which comprises: a) reacting a N-(2-nitrostyryl) enamine with an alkylating agent to afford an imine salt, b) optionally reacting the imine salt with water to afford a (2-nitrophenyl)acetaldehyde, and c) reacting the imine salt or the (2-nitrophenyl)acetaldehyde with a reducing agent capable of selectively reducing the nitro group, to afford the desired 3-alkylated indole.

  制备3-烷基吲哚的方法包括：a) 将N-(2-硝基苯乙烯基)烯胺与烷基化试剂反应，形成亚胺盐，b) 可选地将亚胺盐与水反应，形成(2-硝基苯基)乙醛，以及c) 将亚胺盐或(2-硝基苯基)乙醛与能够选择性还原硝基的还原剂反应，形成所需的3-烷基吲哚。
• Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine
  申请人：Imperial Chemical Industries PLC

  公开号：US05274118A1

  公开（公告）日：1993-12-28

  A process for the preparation of (2R)-methyl-4,4,4-trifluorobutylamine, or an acid addition salt thereof which comprises a) acylating an optically active amine with 2-methyl-4,4,4-trifluorobutanoic acid or a reactive derivative thereof to afford a butyramide; b) separating (R)-diastereomeric butyramide from (S)-diastereomeric butyramide; and c) converting the (R)-diastereomeric butyramide into the desired (2R)-methyl-4,4,4-trifluorobutylamine, or an acid addition salt thereof. The product may be acylated with a carboxylic acid of formula III ##STR1## wherein U is carboxy, or a reactive derivative thereof to afford (R)-4-[5-(N-[4,4,4-trifluoro-2-methylbutyl]carbamoyl)-1-methylindol-3-yl-m ethyl]-3-methoxy-N-o-tolylsulphonylbenzamide. The indole is useful as a leukotriene antagonist, for example in the treatment of asthma or allergic rhinitis.

  制备（2R）-甲基-4,4,4-三氟丁基胺或其酸加成盐的过程包括：a)用2-甲基-4,4,4-三氟丁酸或其反应衍生物酰化手性胺以得到丁酰胺；b)将（R）-对映异构体丁酰胺与（S）-对映异构体丁酰胺分离；c)将（R）-对映异构体丁酰胺转化为所需的（2R）-甲基-4,4,4-三氟丁基胺或其酸加成盐。该产品可与公式III的羧酸进行酰化反应，其中U是羧基或其反应衍生物，以得到（R）-4-[5-(N-[4,4,4-三氟-2-甲基丁基]氨基甲酰)-1-甲基吲哚-3-基甲基]-3-甲氧基-N-邻甲苯磺酰苯甲酰胺。该吲哚化合物可用作白三烯拮抗剂，例如用于治疗哮喘或过敏性鼻炎。
• Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
  申请人：Wyeth

  公开号：US20040198778A1

  公开（公告）日：2004-10-07

  Compounds of Formula (I), 1 are provided where T is CHO, CON, or C(OH)R 1 R 2 ; R 1 and R 2 are hydrogen, optionally substituted lower alkyl, CF 3 , optionally substituted alkenyl, or optionally substituted alkynyl; R 3 is hydrogen or optionally substituted lower alkyl; R 4 is (CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), or (F) n cycloalkyl; n=1-3; R 5 is hydrogen, halogen, CF 3 , diene fused to Y when Y═C, or substituted diene fused to Y when Y═C; W, Y and Z are C, CR 6 or N where at least one of W, Y or Z are C; R 6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO 2 , or NR 7 ; R 7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R 8 is lower alkyl, CF 3 , or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了化学式（I）的化合物，其中T为CHO、CON或C（OH）R1R2；R1和R2为氢、可选取代的低烷基、CF3、可选取代的烯基或可选取代的炔基；R3为氢或可选取代的低烷基；R4为（CF3）n烷基、（CF3）n（取代烷基）、（CF3）n烷基苯基、（CF3）n烷基（取代苯基）或（F）n环烷基；n＝1-3；R5为氢、卤素、CF3、与Y融合的共轭双烯（当Y＝C时）或与Y融合的取代共轭双烯（当Y＝C时）；W、Y和Z为C、CR6或N，其中至少有一个为C；R6为氢、卤素或可选取代的低烷基；X为O、S、SO2或NR7；R7为氢、可选取代的低烷基、可选取代的苯甲基或可选取代的苯基；R8为低烷基、CF3或可选取代的苯基。还描述了制备和使用这些化合物来抑制β淀粉样蛋白的产生以及治疗阿尔茨海默病和唐氏综合症的方法。
• FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF
  申请人：Kreft Anthony Frank

  公开号：US20090227667A1

  公开（公告）日：2009-09-10

  Compounds of Formula (I), are provided where T is CHO, COR 8 , or C(OH)R 1 R 2 ; R 1 and R 2 are hydrogen, optionally substituted lower alkyl, CF 3 , optionally substituted alkenyl, or optionally substituted alkynyl; R 3 is hydrogen or optionally substituted lower alkyl; R 4 is (CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), or (F) n cycloalkyl; n=1-3; R 5 is hydrogen, halogen, CF 3 , diene fused to Y when Y=C, or substituted diene fused to Y when Y=C; W, Y and Z are C, CR 6 or N where at least one of W, Y or Z are C; R 6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO 2 , or NR 7 ; R 7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R 8 is lower alkyl, CF 3 , or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了化学式（I）的化合物，其中T为CHO，COR8或C（OH）R1R2; R1和R2为氢，可选取代的低级烷基，CF3，可选取代的烯基或可选取代的炔基; R3为氢或可选取代的低级烷基; R4为（CF3）n烷基，（CF3）n（取代烷基），（CF3）n烷基苯基，（CF3）n烷基（取代苯基）或（F）n环烷基; n = 1-3; R5为氢，卤素，CF3，与Y融合的二烯或与Y融合的取代二烯，当Y = C时; W，Y和Z为C，CR6或N，其中至少有一个为C; R6为氢，卤素或可选取代的低级烷基; X为O，S，SO2或NR7; R7为氢，可选取代的低级烷基，可选取代的苄基或可选取代的苯基; R8为低级烷基，CF3或可选取代的苯基。还描述了制备和使用这些化合物来抑制β淀粉样蛋白生成以及治疗阿尔茨海默病和唐氏综合症的方法。